CombinedError

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Artivion

NYSE

Free

Artivion's Price growth average in the last 3 years of 13.56% is great compared to market average of 9.66%. This indicates AORT could be a good value stock.

Price growth average in the last 3 years vs Market

Artivion's Owned by insiders of 5.35% is modest compared to market average of 8.74%. This indicates AORT could have a small participation of stakeholders.

Owned by insiders vs Market

Value

Quality

Ownership

Growth

Dividends

is a comprehensive guide for investors seeking income investments. It helps discover stocks with attractive dividend yield trends and growth potential based on historical data.

empowers investors by providing accurate growth forecasts and indicators, enabling them to make proactive choices and build winning portfolios.

reveals confidence through institutional and insider holdings, which help investors understand the dynamics of stock ownership.

assesses a company's operational efficiency, financial health, stability, and growth potential, aiding investment decisions.

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

helps identify undervalued stocks based on fundamentals, ideal for value investors like Warren Buffett.

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

Artivion (AORT)

Keep an eye on Artivion

Take Your Investments to a Whole New Level